Apr 24 |
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
|
Apr 16 |
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
|
Mar 15 |
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
|
Mar 6 |
enVVeno: The Road To Approval Seems Open From Here On
|
Mar 6 |
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
|
Mar 3 |
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
|
Mar 1 |
enVVeno Medical reports FY results
|
Feb 29 |
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
Feb 20 |
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
|
Jan 6 |
enVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitability
|